CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
CELZ$5M
Micro CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaPHOENIX4 employees
Drugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
2
Next Catalyst
May 1, 2026
13dMarket Overview
Stock performance and key metrics
CELZ News
Catalyst Timeline
2 upcoming, 1 past
Phase 2Next
CELZ-201-DDT Phase 2 Results Expected
May 1, 2026EstimatedCELZ-201-DDT45
Primary completion for CELZ-201-DDT trial (NCT06053242) in Chronic Low-back Pain
Source1 more catalyst beyond 14 days
Start a 48h free trial to see all upcoming catalysts
Drug Pipeline
CELZ-201 Administration
Type 1 Diabetes
CELZ-201-DDT
Chronic Low-back Pain
C-peptide
Diabetes Mellitus, Type 1
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CELZ-201 Administration | Phase 2 | Type 1 Diabetes | - | - |
CELZ-201-DDT | Phase 2 | Chronic Low-back Pain | - | - |
C-peptide | Phase 2 | Diabetes Mellitus, Type 1 | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply